Dosage research on Semaglutide

Preclinical research dose ranges

In published preclinical research on Semaglutide, administered dose ranges in rodent studies have most commonly fallen in the 0.01 to 0.5 milligram per kilogram range delivered subcutaneously. Pharmacology studies in mice and rats characterising glucose-lowering and body-weight effects have used doses in this span, with the higher end producing the more pronounced effects on insulin secretion and gastric emptying.

The cardiovascular and atherosclerosis preclinical literature has used doses in a comparable range. Investigators publishing on direct cardiovascular effects (independent of glycaemic effects) have used 0.01 to 0.1 milligram per kilogram subcutaneously in apolipoprotein-E-deficient mice and in other atherosclerosis-prone rodent models across multi-week protocols.

The hepatic and renal endpoint literature has used similar dose ranges, with longer protocol durations to allow tissue-remodeling endpoints to be measured. The pharmacokinetic literature reports an approximate one-week plasma half-life in humans (supporting once-weekly dosing in clinical practice); rodent pharmacokinetics differ and require species-specific dose-translation considerations in protocol design.

Clinical trial dose ranges

The published clinical-trial literature on Semaglutide has tested specific dose levels in type 2 diabetes and obesity contexts. The SUSTAIN type 2 diabetes program used 0.5 mg and 1.0 mg subcutaneously once weekly as the primary tested doses. The STEP obesity program tested 2.4 mg subcutaneously once weekly. The PIONEER oral-formulation program tested 3, 7, and 14 mg oral doses daily.

These doses are reported here as published clinical-trial doses, not as recommendations. Semaglutide is approved by the FDA and Health Canada as a human therapeutic under separate brand names that the Ronin catalog does not market; any clinical use occurs under licensed prescriber care at doses determined by the prescriber, not by reference to research-reagent vials.

Dose-response considerations from the published literature

The published Semaglutide clinical-trial literature has reported dose-response characteristics across the SUSTAIN, PIONEER, and STEP programs. HbA1c reduction and body-weight reduction scaled with dose across the 0.5 mg to 2.4 mg once-weekly subcutaneous range in adults with type 2 diabetes and/or obesity, with the 2.4 mg dose in the STEP-1 obesity trial reporting approximately 15% body-weight reduction over 68 weeks. Cardiovascular outcomes in SUSTAIN-6 used the 0.5 mg and 1.0 mg doses.

Preclinical dose-response work has shown effects scaling with dose across the 0.01 to 0.5 milligram per kilogram rodent range on glucose tolerance, body weight, and insulin secretion endpoints. The cross-species dose-translation depends on the pharmacokinetic differences between rodent and human and on the endpoint being measured.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised Semaglutide vial reconstituted with 1 mL of bacteriostatic water yields a stock concentration of 10 mg per mL. From this stock, a research aliquot of 0.05 mL contains 500 micrograms; an aliquot of 0.024 mL contains approximately 240 micrograms (matching the STEP-1 clinical 2.4 mg weekly dose if dosing on a per-vial basis is desired). Researchers working with rodent pharmacology dose ranges further dilute the stock to a working concentration appropriate to the model and the body weight of the animal subject. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice.

Research-protocol design considerations

Protocol-design choices in the published Semaglutide literature reflect several recurring considerations. Clinical-trial dose selection anchors at 0.5 mg / 1.0 mg / 2.4 mg once weekly subcutaneously for the major published trial designs. Preclinical dose selection anchors at the 0.01 to 0.5 milligram per kilogram range subcutaneously in rodent models.

Route of administration in both clinical and preclinical work is overwhelmingly subcutaneous, with the PIONEER program providing the oral-formulation comparator data. Once-weekly dosing in clinical work is supported by the approximately one-week plasma half-life. Rodent protocols use more frequent dosing cadences (typically two-to-three times weekly) to accommodate the shorter rodent plasma half-life.

The albumin-binding fatty-acid modification that extends Semaglutide’s plasma persistence is a protocol-design consideration in any comparison with other GLP-1 receptor agonists (notably liraglutide, which has a shorter half-life and supports daily rather than weekly dosing). Cross-comparator-arm trials in the published literature use this distinction to characterise the contribution of plasma-persistence to clinical efficacy independent of receptor pharmacology.

References

1. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. [PMID 27633186]
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1). Lancet Diabetes Endocrinology, 2017. [PMID 28110911]
3. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity and Metabolism, 2017. [PMID 28266779]
4. Pratley R et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinology, 2018. [PMID 29397376]
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 2021. [PMID 33567185]
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2). Lancet, 2021. [PMID 33667417]